FIFTH SUPPLEMENTAL INDENTURESupplemental Indenture • May 3rd, 2013 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
FIFTH SUPPLEMENTAL INDENTURE, dated as of April 23, 2013 (the “Fifth Supplemental Indenture”), by and among Medicis Pharmaceutical Corporation (“Medicis”), Valeant Pharmaceuticals International, a Delaware corporation (the “Company”), and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the “Trustee”).
SIXTH SUPPLEMENTAL INDENTURESupplemental Indenture • May 3rd, 2013 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
SIXTH SUPPLEMENTAL INDENTURE, dated as of April 23, 2013 (the “Sixth Supplemental Indenture”), by and among Medicis Pharmaceutical Corporation (“Medicis”), Valeant Pharmaceuticals International, a Delaware corporation (the “Company”), and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the “Trustee”).
SECOND SUPPLEMENTAL INDENTURESupplemental Indenture • May 3rd, 2013 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
SECOND SUPPLEMENTAL INDENTURE, dated as of April 23, 2013 (the “Second Supplemental Indenture”), by and among Medicis Pharmaceutical Corporation (“Medicis”), Valeant Pharmaceuticals International, a Delaware corporation (the “Company”), and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the “Trustee”).
SEVENTH SUPPLEMENTAL INDENTURESeventh Supplemental Indenture • May 3rd, 2013 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
SEVENTH SUPPLEMENTAL INDENTURE, dated as of April 23, 2013 (the “Seventh Supplemental Indenture”), by and among Medicis Pharmaceutical Corporation (“Medicis”), Valeant Pharmaceuticals International, a Delaware corporation (the “Company”) and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the “Trustee”).
FIRST SUPPLEMENTAL INDENTUREFirst Supplemental Indenture • May 3rd, 2013 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE, dated as of April 23, 2013 (the “First Supplemental Indenture”), by and among Medicis Pharmaceutical Corporation (“Medicis”), Valeant Pharmaceuticals International, a Delaware corporation (the “Company”), and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the “Trustee”).
